Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

CALGARY, Oct. 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three and nine-month periods ended September 30, 2007.

Third Quarter Highlights

- Announced positive interim results from a U.K. Phase Ia/1b

combination REOLYSIN(R) and radiation trial for patients with

advanced cancers - including partial and remote responses in patients

with a variety of advanced cancers;

- Commenced patient enrolment in a multi-centre, combination

REOLYSIN(R) and docetaxel (Taxotere(R)) systemic administration trial

in the U.K.;

- In October, received approval from the U.K. regulatory authorities to

begin a combination REOLYSIN(R) and cyclophosphamide trial for

patients with advanced cancers;

- Secured two additional U.S. patents, for a total of more than 150

issued patents worldwide; and,

- Presented preclinical work at the National Cancer Research Institute

Conference in Birmingham, U.K. demonstrating for the first time how

reovirus-infected melanoma cells stimulate dendritic cells to prime

the immune system against cancer cells.

"With positive results being reported from our clinical trial program in the U.K. and the U.S., seven trials actively enrolling, an additional combination trial approved to begin and an expanding intellectual property portfolio supporting our technology, Oncolytics is looking forward to making substantial progress through the balance of 2007 and 2008," said Dr. Brad Thompson, President and CEO of Oncolytics.

Oncolytics Biotech Inc.

BALANCE SHEETS

(unaudited)

As at,

September 30, December 31,


'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 2015 , ... Rainbow Scientific, Inc. (RSI), a North American ... BI’s line of human mesenchymal stem cell (hMSC) differentiation media, MSC go ... complete system for multipotency evaluation of hMSCs and reliable induction of hMSCs into ...
(Date:7/28/2015)... July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines to ... Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a recently-formed ... ( c. £76.5m), gross, from blue chip institutional investors ...
(Date:7/28/2015)... , July 28, 2015  PDL BioPharma, Inc. ... announced that the Company will release its second quarter ... 2015, on Wednesday, August 5, 2015, after market close. ... that day at 4:30 p.m. Eastern Time to discuss ... call will be available via the webcast link on ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... than EUR 1.022 billion in 2013; while production volume reached close to 1.84 ... producing country with a share of 75.5% of the region’s total aluminium hydroxide ...
Breaking Biology Technology:Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3
... Advice Shared Through Dynamic WikiAnswers Q&A ... ... a show of support for National,Breast Cancer Awareness Month, Answers.com,s question ... ), where breast cancer survivors,friends and family have gathered to ask ...
... Win Needed Medical ... Oct. 22 Television medical dramas such as,ER and House ... country to millions of Americans each week. Now, small hospitals,lacking ... - are being given the opportunity to turn the cameras ...
... 22 Genzyme Corp.,(Nasdaq: GENZ ) today ... granted marketing approval for Renvela(TM) (sevelamer carbonate) for,the ... kidney disease on,dialysis. Renvela is a next-generation version ... the United States. "Since its approval in ...
Cached Biology Technology:Answers.com's WikiAnswers Supervisors Rallying for National Breast Cancer Awareness Month 2Answers.com's WikiAnswers Supervisors Rallying for National Breast Cancer Awareness Month 3American M.R.I.-DOL: Small Hospitals To Turn The Camera On Themselves In Unique National Contest 2American M.R.I.-DOL: Small Hospitals To Turn The Camera On Themselves In Unique National Contest 3FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 2FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 3FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 4FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 5
(Date:7/2/2015)... , June 25, 2015 ... the addition of the "Natural Language Processing ... (Recognition, IVR, OCR, Pattern & Image Recognition) - ... offering. The key vendors occupying the ... IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... Award-Winning Fingerprint Recognition Solution for HIPAA ... ... Operational Efficiencies, ATLANTA, Jan. 22 M2SYS Technology, ... has enhanced its OnRecord(TM) healthcare solution for emergency,departments and ...
... Scientists studying microbial communities and the growth of sedimentary ... have made a surprising discovery about the geological record ... how certain sequences of sedimentary rock are dated, and ... other planets., We found microbes change the rate at ...
... that it has been named an American Society ... Center of Excellence. The ASMBS Center of ... track record of favorable outcomes in bariatric surgery. ... of our experienced surgeons and our institutional commitment ...
Cached Biology News:LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 2Hot springs microbes hold key to dating sedimentary rocks, researchers say 2Pennsylvania Hospital recognized for excellence in bariatric surgery 2
... ReadyPrep 2-D starter kit is intended for first-time ... IPG strips. The kit includes a protein sample ... to second-dimension gels six 17 cm, ten 11 ... (ReadyStrip IPG strips and precast SDS-PAGE gels and ...
... Phosphate Phosphatase 2 (LPP2) ... aqueous solution Solution ... containing 0.08% sodium azide. ... the human LPP2 protein. ...
... Phospho-Specific(Thr 222 ) ... 10 mM sodium HEPES, 100 ... 7.5. Recognizes the ~47 kDa ... (MAPKAPK-2) protein phosphorylated at Thr ...
Rabbit polyclonal to SMURF 2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide (10-30 aa in length) at the N-term of first 50 aa of human SMURF 2. Entrez G...
Biology Products: